Vedere Bio logo

Vedere Bio Funding & Investors

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.

vederebio.com

Total Amount Raised: $98,000,000

Vedere Bio Funding Rounds

  • Series A

    $77,000,000

    Series A Investors

    Octagon Capital Advisors
    Mission BioCapital
    Samsara BioCapital
    Atlas Venture
    Casdin Capital
    RD Fund
  • Series A

    $21,000,000

    Series A Investors

    Atlas Venture
    Mission BioCapital
    Foundation Fighting Blindness
Funding info provided by Diffbot.